Cochrane · systematic review · CD008919
Antioxidant treatments for schizophrenia
Magalhães, PVS, Dean, O, Andreazza, AC, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 4 · 57.1%Moderate 1 · 14.3%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Adjunctive antioxidants for schizophrenia versus placebo
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: improvement, short term PANSS Adjunctive antioxidants for schizophrenia vs placebo | RR 0.77 [0.53, 1.12] | 3 studies · 229 participants | Low Downgraded: risk of bias, inconsistency |
Total PANSS scores, short term PANSS Adjunctive antioxidants for schizophrenia vs placebo | no estimate extracted | 7 studies · 584 participants | Very low Downgraded: risk of bias, inconsistency |
Total BPRS scores, short term BPRS Adjunctive antioxidants for schizophrenia vs placebo | no estimate extracted | 8 studies · 843 participants | Low Downgraded: risk of bias, inconsistency |
General functioning ‐ short term GAS Adjunctive antioxidants for schizophrenia vs placebo | no estimate extracted | 2 studies · 52 participants | Low Downgraded: risk of bias |
General functioning ‐ medium term GAS Adjunctive antioxidants for schizophrenia vs placebo | no estimate extracted | 1 study · 135 participants | High |
Leaving the study early, short term Adjunctive antioxidants for schizophrenia vs placebo | RR 0.73 [0.48, 1.11] | 16 studies · 1584 participants | Moderate Downgraded: risk of bias, inconsistency |
Adverse effects: 1. Serious (any time point) ‐ any serious adverse effect Various methods Adjunctive antioxidants for schizophrenia vs placebo | RR 0.65 [0.19, 2.27] | 3 studies · 234 participants | Low Downgraded: risk of bias |